Haines, Brian B.

An unbiased oncology compound screen to identify novel combination strategies

O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics

PI3K/AKT/mTOR signaling in cancerComputational Drug Discovery Methods

Cited by 407

Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes

McManus, M. T., Haines, B. B., Dillon, C. P., Whitehurst, C. E., van Parijs, L., Chen, J., & Sharp, P. A. (2002) · The Journal of Immunology

RNA Interference and Gene DeliveryRNA Research and Splicing

Cited by 215

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 152

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters

Histone Deacetylase Inhibitors ResearchEnzyme function and inhibition

Cited by 93

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research

Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research

Cited by 9